Teva Pharmaceutical Industries (TEVA) Rating Lowered to Underperform at Wells Fargo & Co

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by analysts at Wells Fargo & Co from a “market perform” rating to an “underperform” rating in a research note issued on Friday. They currently have a $17.00 price target on the stock. Wells Fargo & Co’s target price suggests a potential downside of 13.18% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. BTIG Research increased their target price on shares of Teva Pharmaceutical Industries to $20.00 in a research report on Friday, December 15th. Gabelli reiterated a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, September 13th. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Evercore ISI set a $38.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Wednesday, October 25th. Finally, Goldman Sachs Group upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Friday, December 15th. Seven equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $21.16.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $19.58 on Friday. The company has a market cap of $19,390.00, a PE ratio of -3.34 and a beta of 0.54. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries has a 12-month low of $10.85 and a 12-month high of $38.15.

A number of hedge funds have recently made changes to their positions in TEVA. Capital Research Global Investors boosted its stake in shares of Teva Pharmaceutical Industries by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares during the period. FMR LLC boosted its stake in shares of Teva Pharmaceutical Industries by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares during the period. Northern Cross LLC boosted its stake in shares of Teva Pharmaceutical Industries by 14.0% in the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after purchasing an additional 2,184,172 shares during the period. Nordea Investment Management AB boosted its stake in shares of Teva Pharmaceutical Industries by 2.5% in the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after purchasing an additional 311,894 shares during the period. Finally, Alliancebernstein L.P. boosted its stake in shares of Teva Pharmaceutical Industries by 32.3% in the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after purchasing an additional 2,782,257 shares during the period. 51.98% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries (TEVA) Rating Lowered to Underperform at Wells Fargo & Co” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3126684/wells-fargo-co-downgrades-teva-pharmaceutical-industries-teva-to-sell.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.